

SONY

See how the ID7000™ system is being used by researchers to accelerate discovery

Peruse the peer-reviewed research articles, reviews and protocols, to see which fits your application needs.

[Download Publications List](#)



ID7000™ Spectral Cell Analyzer

The Journal of Immunology

ABSTRACT | MAY 01 2024

Longitudinal multiomic analysis associates T cell dynamics with recurrence of ovarian cancer after chemotherapy **FREE**

Rachel Ng; ... et. al

J Immunol (2024) 212 (1_Supplement): 0456_5804.

<https://doi.org/10.4049/jimmunol.212.supp.0456.5804>

Related Content

Multiomic Spatial Phenotyping of the Tumor Immune Microenvironment at Single Cell Resolution

J Immunol (May,2023)

Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy

J Immunol (April,2023)

Autophagy-deficient breast cancer shows early escape from dormancy and recurrence following chemotherapy

J Immunol (May,2018)

Longitudinal multiomic analysis associates T cell dynamics with recurrence of ovarian cancer after chemotherapy

Rachel Ng^{1,3}, Dan Yuan¹, Inyoul Lee¹, Sarah Li¹, Pamela Troisch¹, Sergey Kornilov¹, Brett Smitt¹, Andrew Magis¹, Kim Murray¹, Rick Edmark¹, Charles Drescher², James Heath¹

¹Inst. for Sys. Bio., ²Swedish Cancer Inst., ³Univ. of Washington

In the US, ovarian cancer is a relatively rare but lethal cancer that causes the 5th most cancer deaths in women. Current standard of care involves surgery and chemotherapy. While there are attempts to introduce immunotherapy, clinical trials of immune checkpoint blockade showed limited effect thus far. There is a need to understand the cancer-intrinsic and patient-intrinsic factors that would affect patient outcome, especially factors related to immune engagement. We performed deep multiomic longitudinal analysis of 29 ovarian cancer patients before and after chemotherapy. We analyzed blood plasma proteomics and metabolomics, and profiled 132,124 circulating T cells for single-cell whole transcriptome, surface proteins, and T cell receptor sequences. Our characterization of patients' longitudinal response identified biomarkers and T cell dynamics predicting patient outcome.

SESSION: T Cells in Cancer III (AM)

FUNDING: Andy Hill Cancer Research Endowment Fund, the Wilke Family Foundation, and the Parker Institute for Cancer Immunotherapy